Your browser doesn't support javascript.
Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers.
Miyakawa, Kei; Kato, Hideaki; Ohtake, Norihisa; Stanleyraj Jeremiah, Sundararaj; Ryo, Akihide.
  • Miyakawa K; Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
  • Kato H; Infection Prevention and Control Department, Yokohama City University Hospital, Kanagawa, Japan.
  • Ohtake N; Advanced Medical Research Center, Yokohama City University, Kanagawa, Japan.
  • Stanleyraj Jeremiah S; Bioscience Division, Research and Development Department, Tosoh Corporation, Tokyo Research Center, Kanagawa, Japan.
  • Ryo A; Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
J Infect Dis ; 2022 Aug 18.
Article in English | MEDLINE | ID: covidwho-2243385
ABSTRACT
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 mRNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that three antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several post-booster breakthrough cases caused by the Omicron variant.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Infdis